Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007793 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
A Phase 3 study of Primary Hyperaldosteronism, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07007793: Recruiting Phase 3 study of Primary Hyperaldosteronism, sponsored by AstraZeneca.
NCT07007793 is a Phase 3 study of Primary Hyperaldosteronism that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07007793, a Phase 3 study of Primary Hyperaldosteronism, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and 12 countries.
Primary Outcome
To assess the effect of baxdrostat versus placebo on seated Systolic Blood Pressure (SBP) at Week 8
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baxdrostat
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - San Francisco
Illinois
- Research Site - Chicago
- Research Site - Springfield
Massachusetts
- Research Site - Boston
- Research Site - Boston
Ohio
- Research Site - Cleveland
- Research Site - Columbus
Pennsylvania
- Research Site - Bethlehem
- Research Site - Philadelphia
Connecticut
- Research Site - Farmington
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2028-02-18 |
| Phase | Phase 3 |
What NCT07007793 shows while recruiting
NCT07007793 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Primary Hyperaldosteronism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07007793 names 20 study sites across 15 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07007793 about?
NCT07007793 is a clinical study titled "A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism". This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone Syste...
What is the current status of trial NCT07007793?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-08-07. Estimated completion is 2028-02-18.
What conditions does trial NCT07007793 study?
This clinical trial studies the following conditions: Primary Hyperaldosteronism.
What interventions are being tested in trial NCT07007793?
The interventions under investigation include: Placebo (DRUG), Baxdrostat (DRUG).
Who is sponsoring clinical trial NCT07007793?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007793 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Hyperaldosteronism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07007793's enrollment target sits among peer trials
180 1423rd of 2000 higher than 564 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI